Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.
Laura J HavrileskyJui-Chen YangPaula S LeeAngeles Alvarez SecordJessie A EhrismanBrittany A DavidsonAndrew BerchuckKathleen M DarcyG Larry MaxwellShelby D ReedPublished in: Cancer (2019)
Patients would accept a moderately higher risk of perioperative complications and surgical mortality in exchange for substantial gains in survival. These quantitative findings provide clinicians with a framework to discuss preferences with patients and to incorporate preferences into clinical trial design.
Keyphrases
- neoadjuvant chemotherapy
- newly diagnosed
- clinical trial
- locally advanced
- end stage renal disease
- lymph node
- sentinel lymph node
- ejection fraction
- risk factors
- decision making
- chronic kidney disease
- high resolution
- palliative care
- cardiac surgery
- prognostic factors
- cardiovascular events
- rectal cancer
- patients undergoing
- peritoneal dialysis
- acute kidney injury
- mass spectrometry
- combination therapy
- patient reported
- double blind